ORA-Sweet® **SF**

Sugar-Free Flavored Oral Syrup Vehicle



ORA-Sweet SF is a sugar-free, alcohol-free syrup vehicle used to simplify the process of flavoring and sweetening extemporaneous compounded sugar-free oral preparations. ORA-Sweet SF allows the pharmacist to formulate elegant, sugar-free sweetened products with minimum time and maximum dependability. It is flavored with a citrus-berry blend for a highly palatable taste.

Applications

ORA-Sweet SF may be used alone or in combination with other agents. ORA-Sweet SF will retain its flavoring properties when diluted up to 50% with water or suspending agents. Its versatility makes it ideal for the flavoring of:

- Pediatric suspensions
- Geriatric suspensions

How to Use

ORA-Sweet SF is the ideal flavoring and sweetening agent for many suspensions, but it is specially formulated to complement Perrigo's suspending vehicle ORA-Plus®. ORA-Sweet SF and ORA-Plus can be combined in a 50/50 ratio to produce a pleasant tasting elegant suspension.

Properties

ORA-Sweet SF does not contain sugar or alcohol. A small amount of sodium saccharin imparts sweetness to ORA-Sweet SF. Xanthan gum, glycerin and sorbitol contribute to both texture and good flow characteristics. ORA-Sweet SF contains flavoring agents to increase palatability. ORA-Sweet SF is buffered to a slightly acidic pH to help diminish degradation of medicinal agents through oxidation.

Contains:

Purified water, glycerin, sorbitol, sodium saccharin, xanthan gum, and berry citrus flavor (contains FD&C Red #40). Buffered with citric acid and sodium citrate. Preserved with methylparaben (0.03%), propylparaben (0.008%), and potassium sorbate (0.1%).

Specifications

Appearance: Clear liquid with a slight tint

pH range: 4.0 - 4.4

Taste: Sweet citrus-berry flavor

Osmolality: Approximately 1979 mOsm/kg

Available through your wholesaler or distributor.



ORA-Sweet® **SF**

Compounding Examples



ALPRAZOLAM 1 mg/mL, 120 mL²

Alprazolam 2 mg/tablet ORA-Plus ORA-Sweet SF* 60 tablets 60 mL q.s. 120 mL

- Expiration 60 days
- Protect from light
- · Shake well before using

LABETALOL HYDROCHLORIDE 40 mg/mL, 120 mL¹

Labetalol HCl 300 mg/tablet ORA-Plus ORA-Sweet SF* 16 tablets 60 mL q.s. 120 mL

- Expiration 60 days
- Protect from light
- · Shake well before using

SPIRONOLACTONE 5 mg/mL plus HYDROCHLOROTHIAZIDE 5 mg/mL, 120 mL¹

Spironolactone-Hydrochlorothiazide

 25 mg/25 mg/tablet
 24 tablets

 ORA-Plus
 60 mL

 ORA-Sweet SF*
 q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

HYDRALAZINE HYDROCHLORIDE 4 mg/mL, 100 mL²

Hydralazine Hydrochloride 100 mg/tablet 4 tablets
ORA-Plus 50 mL
ORA-Sweet SF c.s. 100 mL

- Expiration 2 days
- Protect from light
- Shake well before using
- Store in refrigerator

METOPROLOL TARTRATE 10 mg/mL, 120 mL¹

Metoprolol Tartrate 100 mg/tablet ORA-Plus ORA-Sweet SF* 12 tablets 60 mL q.s. 120 mL

60 mL

q.s. 120 mL

- Expiration 60 days
- Protect from light
- Shake well before using

VERAPAMIL HYDROCHLORIDE 50 mg/mL, 120 mL Verapamil HCl 80 mg/tablet 75 tablets

Verapamil HCl 80 mg/tablet ORA-Plus

ORA-Sweet SF*

- Expiration 60 daysProtect from light
- Flotect Holli light
- · Shake well before using

General Directions for Compounding ORA-Sweet SF*/ORA-Plus Suspensions

ORA-Sweet SF and ORA-Plus should be combined in a 50/50 ratio to achieve optimal formulation.

- Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples to the left.) It may be wise to add approximately 10% overage for compounding losses.
- Crush tablets with a mortar and pestle to a <u>fine</u> powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.
- Add a small amount of ORA-Plus and triturate to a thick, <u>smooth</u> paste. Add the remainder of the ORA-Plus by geometric dilution. The amount of ORA-Plus should be 50% of the total solution.
- Bring the suspension to a final volume using ORA-Sweet SF*. Mix briefly with a mortar and pestle until a uniform suspension is formed.
- Dispense in a tight, light resistant amber bottle with appropriate labeling.
- Label with an expiration date. If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.
- Depending on the medicinal agent used, label containers "Shake Well Before Using", "Protect From Light", and "Keep Refrigerated".

*ORA-Sweet SF may be substituted with ORA-Sweet. Both products may be used in a 1:1 ratio with ORA-Plus. ¹American Journal of Health-System Pharmacists 1996: 53:2304-2309.

²American Journal of Health-System Pharmacists 1998: 55:1915-20.

Contraindications

 $\mbox{ORA-Sweet SF}$ is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.

DISCLAIMER:

All information presented is intended to demonstrate the application of Perrigo vehicles in compounding. The information and examples provided in this paper have not been evaluated by the Food and Drug Administration and are provided for educational purposes only. Any information and examples provided are not intended to replace the advice of a physician or take the place of good pharmaceutical compounding practices. The preparation, dispensing, and administration of pharmaceuticals is the responsibility of licensed medical professionals and must adhere to current pharmaceutical compounding requirements and lawful practice of medicine. Perrigo assumes no liability for any injury and/or damage to persons from use of any information and/or examples contained in this document. Perrigo does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process. Vehicle purchasers assume all risks of patent infringement by reason of any such use, combination or operation. Before compounding any prescription drug with Perrigo vehicles, please review the full prescribing information of the prescription drug for important safety information and limitations of use.

© 2019 Perrigo Company, plc 6J3-AID01-ver01-01 Trademarks held by their respective owners.

